News

TGF-β pathway inhibitors for the treatment of bone marrow failure in Fanconi anemia

Fanconi anemia (FA) patients suffer from progressive bone marrow failure due to the defective hematopoietic stem cells (HSCs) in their bone marrow. The mechanisms of why the HSCs in FA patients are defective remain elusive. Recent studies suggest that DNA...

Read More >

The prevention of DNA damage in Fanconi anemia HSC by ALDH activators

The cause of injury and loss of blood-forming stem cells (Hematopoietic Stem Cells, HSC) in Fanconi anemia is due to abnormal repair of a specific type of DNA damage in which two DNA strands get permanently knotted to each other....

Read More >

Use of triplex-forming PNAs as a strategy for correction of the FA phenotype

As a monogenic blood disorder with potential survival disadvantage, Fanconi anemia has long been considered an attractive target for conventional gene therapy but success has been elusive. Consequently, there has been increasing interest in developing techniques to catalyze correction of...

Read More >

A Training Grant for Development of a Fanconi Anemia Cohort in Mexico

This is a training grant for a medical geneticist from Mexico City, who will develop a registry and subsequently a cohort of patients with FA who reside in Mexico. The project addresses one of the research priorities of the FARF:

Read More >

Cancer in Heterozygote Carriers of Fanconi Anemia

Fanconi anemia increases the risk of cancer as individuals' age. This is likely due to defects in the Fanconi DNA repair pathway that lead to the formation of rare cancer-causing mutations. Fanconi anemia individuals are defective in both copies of...

Read More >

Detection and characterization of ubiquitinated FANCD2 and FANCI

Fanconi anemia is caused by mutations in number of genes involved in DNA repair. Two key players are genes called FANCD2 and FANCI. These genes serve as central regulators of the Fanconi DNA repair pathway. Dr. Deans and others have...

Read More >